3 About The Royal Marsden 3 At The Royal Marsden, we deal with cancer every day so we understand how valuable life is. And when people entrust their lives to us, they have the right to demand the very best. That s why the pursuit of excellence lies at the heart of everything we do.
4 Annual Report and Accounts 2009/10 4
5 5 Contents About The Royal Marsden 6 Who we are 8 Ten facts about The Royal Marsden 10 Chairman and Chief Executive joint statement 13 What we do 16 Referral 18 Diagnosis 20 Treatment 26 Care 30 Ongoing support 32 Research 39 Our staff 45 Our charity Our performance 49 Quality account 50 Statement on quality from the Chief Executive 52 Priorities for improvement 64 Statements of assurance from the Board 82 Performance against key metrics 85 Valuing people 86 Staff engagement 90 Equality and diversity 95 Sustainability 99 Governance 100 Membership 104 Our Board of Directors 108 The work of our Board 112 The Management Executive 114 Regulatory findings 117 Finance 118 Directors Report 120 Remuneration Report 122 Financial review for year ended 31 March Annual Accounts for the year ended 31 March 2010
6 Annual Report and Accounts 2009/10 6 Who we are The Royal Marsden NHS Foundation Trust is a world leader in cancer research, science and education. We have two hospitals: one in Chelsea, London, and a health and science campus in Sutton, Surrey. We also have a Medical Daycare Unit which we run in partnership with Kingston Hospital. We work closely with The Institute of Cancer Research (ICR) and together we are the only National Institute of Health Research (NIHR) Biomedical Research Centre specialising in cancer in the UK. We work in partnership to undertake groundbreaking research into new cancer drug therapies and treatments. The partnership makes us the largest comprehensive cancer centre in Europe with a combined staff of 3,500. The Royal Marsden and the ICR recently announced a new academic partnership with Mount Vernon Cancer Centre which, through translational research linked to clinical trials, will make a major contribution to improvements in personalised medicine and patient care. This year, the Trust celebrated six years as an NHS foundation trust. We were one of the first hospitals to be awarded this status in April 2004.
7 About The Royal Marsden 7
8 8 Ten facts about The Royal Marsden Annual Report and Accounts 2009/10 The Royal Marsden was founded in 1851 by William Marsden. His vision was to create a pioneering cancer hospital dedicated to excellence in the study, treatment and care of people with cancer. Today we continue to build on this legacy, constantly raising standards to improve the lives of patients from across the UK and abroad. 1The Royal Marsden is a first wave NHS foundation trust and is ranked as one of the best performing trusts in the country. We are the only foundation trust to be awarded the highest possible score of double excellent for quality of services and quality of financial management in the Care Quality Commission s (CQC) Annual Health Check four years in a row. 2With our academic partners The Institute of Cancer Research (ICR), we are the largest comprehensive cancer centre in Europe. We offer leading-edge treatment in surgery, chemotherapy and radiotherapy, supported by world-class innovation and discovery by our clinical and scientific teams. 6As a specialist hospital, The Royal Marsden works with a range of partners to benefit patients. This includes Kingston Hospital for the local delivery of chemotherapy services and The Royal Brompton and Chelsea and Westminster Hospitals for surgery, respiratory medicine and palliative care. We have just launched an academic partnership with the Mount Vernon Cancer Centre to enhance cancer research across London and Hertfordshire. 7We are the largest NHS provider of molecular diagnostics in the UK, allowing us to identify patients who would benefit from specific anti-cancer therapies and to tailor treatment programmes to the individual.
9 About The Royal Marsden 9 3The Royal Marsden and the ICR work across the boundaries of medicine and science and together our activities span basic science, and translational and clinical research. In the last year, we recruited over 4,000 patients to more than 450 clinical research projects to help us improve treatment and outcomes for patients worldwide. 4The CQC s 2009 National Inpatient and Outpatient Surveys both showed that patients rated us in the top 20% of hospitals in the country for their experience of care. 5The Royal Marsden is due to open some major new facilities shortly including a 16 million new Children s and Young Persons Centre and a 20 million Centre for Molecular Pathology, both of which will provide the most advanced personalised treatment for our patients. 8As a leader and innovator in cancer care, The Royal Marsden is among the first in the NHS to provide the very latest in cancer technology and treatments including the da Vinci S surgical robot, Cyberknife VSI1, PET/CT scanners, image-guided radiotherapy and intensitymodulated radiotherapy. 9The Royal Marsden is consistently one of the highest scoring trusts in the country for staff satisfaction and for staff who would recommend it as a place to work. 10In the past year, The Royal Marsden School of Cancer Nursing and Rehabilitation educated over 400 nurses and allied health professionals. The Royal Marsden Manual of Clinical Nursing Practice is the best-selling nursing textbook in the UK.
10 Chairman and Chief Executive joint statement 10 Annual Report and Accounts 2009/10 The Royal Marsden has a vital role in championing change and improvement in cancer care through research and innovation, education and leading-edge practice. Together with the Institute of Cancer Research (ICR), we form one of the largest comprehensive cancer centres in Europe, offering expert treatment supported by high quality research. We are designated as a specialist Biomedical Research Centre by the NIHR and operate in partnership with a range of other organisations whenever this will benefit patients. Our aim is to contribute to global improvement in the effective treatment of cancer as well as local treatment and care of the highest quality. During 2009/10, The Royal Marsden achieved a rating of excellent for quality of service and quality of financial management in the CQC s Annual Health Check. The Trust has achieved the highest rating possible for nine consecutive years and has also been given the Customer Service Excellence Award for all its services, including the Chemotherapy Suite run by The Royal Marsden at Kingston Hospital. The Annual Inpatient Survey, undertaken across the NHS, shows that patients rate the quality and experience of care they receive from The Royal Marsden with high scores for the privacy afforded and dignity shown to them. As an NHS foundation trust, The Royal Marsden has a strong risk rating of four from the independent regulator Monitor and has achieved its planned financial surplus at the end of 2009/10 to reinvest in services and facilities in the year ahead. The effective diagnosis and management of patients with cancer remains one of the major challenges in healthcare today, with the rising incidence of cancer worldwide and the speed of technological advance. Our service strategy continues to focus on the comprehensive provision of services across all tumour types and all treatment modalities. We have made a 30 million investment in a new Ambulatory Care Centre, new theatres and a 19 bed Critical Care Unit in Chelsea to ensure patients are treated in the best and most modern and efficient environment for all their needs from day care to specialist surgery. At Sutton, we are due to complete a new 16 million Children s and Young Persons Centre in 2011, built in conjunction with the Teenage Cancer Trust, to respond to a significant increase in demand for this area of our service. This forms part of our strategy to enhance our site at Sutton as a health and science campus, incorporating a full range of services and co-located research facilities including our Drug Development Unit. During 2009/10, The Royal Marsden and the ICR were selected as an academic partner for Mount Vernon Cancer Centre by East and North Hertfordshire NHS Trust. We are delighted to be formally launching the partnership in June 2010, with the aim of integrating research structures and maximising the contribution all partner organisations make to research into better ways of diagnosing and treating cancer. We look forward to building partnerships with other organisations in research, treatment and professional education whenever this will benefit patients. Our plans for the future are ambitious and essential if we are to fulfil our mission to make a difference to cancer research and treatment globally. We are strengthening the interaction with the ICR with the appointment of Professors David Cunningham and Alan Ashworth as Co-Directors of Research Integration. Together, we are building a Centre for Molecular Pathology which will allow us to develop new approaches in personalised medicine and achieve the best results for patients. Increasingly, we are able to personalise the delivery of therapeutics by identifying which tumours respond to specific drugs and other modalities of treatment. The Centre for Molecular Pathology will enhance and extend the work we already undertake in molecular diagnostics and drug development to make a real difference to patients worldwide.
11 About The Royal Marsden 11 Left to right: Miss Cally Palmer CBE, Chief Executive and Mrs Tessa Green CBE, Chairman. Innovation and discovery are challenging in a tough economic climate and all our staff are working hard to ensure treatment and care is given as efficiently as possible so that we can continue to invest in excellent facilities and the best service for patients. This means changing the way we work, delivering care at home when possible and minimising inpatient stays in hospital. Our aim is to ensure that quality remains at the centre of our service and that efficiency is visible to patients only as a positive experience of care. Cally Palmer CBE Chief Executive Tessa Green CBE Chairman This has been a year of immense achievement and progress. We would like to take this opportunity to thank the staff of The Royal Marsden for their exceptional commitment and professionalism which are commented on by so many of our patients.
12 Annual Report and Accounts 2009/10 12
13 What we do 13 It is estimated that one in three people will be diagnosed with cancer at some point in their life. Even for those who have not been personally affected, it is likely that someone they know has gone through their own cancer experience. About The Royal Marsden For this reason, treating patients as individuals is at the heart of our patient-centred approach. In the following pages, we present some of the achievements from the last year which will allow us to continue to deliver personalised cancer care along each step of the patient pathway.
14 What we do 14 Annual Report and Accounts 2009/10 Referral General Practitioners (GPs) play a key role in assessing symptoms and referring patients for specialist diagnosis. Developing interactions that build our relationship with GPs is therefore vital to give patients fast access to care. Diagnosis A fast and accurate diagnosis contributes to better outcomes for patients. Our Rapid Diagnostic and Assessment Centre provides patients with immediate access to a specialist team and expert diagnostics, including digital imaging and molecular diagnostics to help sub-classify cancer types. Research As a world-class cancer centre, The Royal Marsden works with The Institute of Cancer Research to accelerate research from bench to bedside. Together, we apply knowledge about the basic science of cancer to clinical research and treatment. Our work has been internationally recognised and has led to a better understanding of the causes of cancer and ways of treating it more effectively.
15 Care Our approach to care is patient-centred. This means we consistently strive to improve the patient experience in hospital and use our expertise to tailor care to meet the needs of individual patients. 15 About The Royal Marsden Treatment We offer a comprehensive range of services, from surgery to radiotherapy and chemotherapy in state-of-the-art facilities. A multidisciplinary team of experts works together to plan each patient s course of therapy in order to achieve the optimum outcome. Ongoing support With increasing emphasis on treating cancer as a chronic disease, we have in place the essential support to help patients feel empowered and educated about their ongoing health.
16 What we do 16 Annual Report and Accounts 2009/10 Referral For many patients, the first and most consistent point of contact in their cancer pathway is their GP. In order to assist GPs in making timely referrals, we have published and distributed a directory of services. Working closely with GPs in this way can increase early diagnosis and achieve better outcomes. Providing faster access has also been a priority over the last year and our Breast Unit has demonstrated success by surpassing the new national standard. Building relationships with GPs GPs play a critical role in the cancer care pathway, from referral and diagnosis to supporting patients through treatment and co-ordinating their follow-up care. That s why The Royal Marsden has launched the GP Education Series, a calendar of quarterly one-day seminars that allow us to contribute to GPs professional knowledge. Each GP Education Day covers several tumour types and examines aspects of cancer diagnosis, treatment and research relevant to GPs the latest in screenings, what symptoms to look for and when to refer. The programme for each seminar is planned and delivered by a multi-disciplinary team of clinical experts and consultants through lectures, case studies and interactive panel discussions. The event is filmed and edited for webcast which means that GPs who cannot attend can still access the learning online. Over 200 GPs have attended the first two GP Education Days which took place in September 2009 and April The positive feedback from participants continues to help shape the programme for the rest of the Series. Demonstrating swifter referral times Our Breast Unit has exceeded the new standard brought in by The Department of Health in early Over 98% of new GP patient referrals are now seen within 14 days of referral and over half are seen within one week. This surpasses the national target which was set at 93% of breast symptomatic patients to be seen within two weeks. Achieving these results has been greatly aided by prompt referrals to our state-of-the-art Rapid Diagnostic and Assessment Centre which offers quick and effective diagnosis with a fast-track through treatment if required. These results go a long way to show our desire to support primary care and we continue to grow our responsive diagnostic practice for common cancers such as breast cancer. Our goal is to reduce waits to just 72 hours while speeding up the turnaround times for biopsy results. Genetic assessment services Genetic assessment has become a vital part of the services we offer to individuals and families referred to us with a concern about a risk of inherited cancer. This involves assessment for breast, ovarian, colorectal and rarer cancers and includes a risk estimation using a family history, screening advice and genetic testing when necessary. We have aimed to make the service more accessible, ensuring that GPs understand when patients should be referred. Our team also works closely with primary care to advise on riskreduction and management so that those who are referred to us can make informed decisions about their health.
17 Referral About The Royal Marsden 17 By running the GP Education Series, the Trust s specialists are giving us an opportunity to improve our awareness of the detection and up-to-date management of specific cancers and, in the process, helping us to aspire to the best possible care for our patients. Dr Shuman Hussein, GP Principal, The Surgery, Stanhope Mews West
18 What we do 18 Annual Report and Accounts 2009/10 Diagnosis Early diagnosis is essential in achieving better outcomes for patients with cancer. We provide patients with immediate access to a specialist team and expert diagnostic services through our Rapid Diagnostic Assessment Centre (RDAC). Our focus is on relieving patient anxiety through quick results and a modern environment. We also continue to develop specialised molecular diagnostics which allow us to individualise treatment for patients. Leading the way in targeted molecular diagnostics The concept of personalised medicine stems from the knowledge that cancer is a heterogeneous disease. This means that patients with the same type of cancer may respond differently to the same treatment. Molecular diagnostics tools can help sub-classify cancer types to identify patients who may see greater benefit from specific therapies, at the same time reducing the potential severe side effects. The final goal of this approach is providing therapies that are tailored to the individual patient s needs as opposed to the traditional one-size-fitsall approach of conventional chemotherapy. In the UK, The Royal Marsden is leading the way in providing our patients with routine molecular diagnostics for biomarkers that are clinically relevant in cancer. We are the largest NHS provider of routine molecular diagnostics in the country. We are at the forefront of introducing molecular diagnostics as standard into clinical practice to benefit patients with various cancer types. In the past year, our joint Royal Marsden and ICR molecular diagnostics lab, in conjunction with our Lung Unit, was the first UK centre to routinely start testing for mutations in the EGFR gene in lung cancers of patients. Genotyping, as it is known, enables us to identify patients with an EGFR mutation who would benefit from targeted therapy over more traditional chemotherapy. These patients often have dramatic improvement in their symptoms sometimes within days of treatment and with no major side effects. The Rapid Diagnostic and Assessment Centre Improving access to better and more rapid cancer diagnosis for our patients is a priority at The Royal Marsden. Our one-stop consultant-led RDAC provides diagnostic services for patients with a range of suspected cancers. Patients referred into RDAC for diagnostic service have immediate access to a multi-disciplinary team of experts including a consultant surgeon, consultant radiologist, consultant pathologist and clinical nurse specialist. Assessments are made using the latest diagnostic techniques such as digital mammography and vacuumassisted biopsy which enable biopsies to be taken and examined quickly, ensuring diagnosis is made without any delay. Within the Breast Unit, this also involves the gold-standard triple assessment process which utilises three diagnostic measures. Perhaps the greatest benefit to patients is that, in most cases, all of these investigations can be conducted during just one clinic visit. Most patients can receive their diagnosis the same day which significantly reduces the waiting time and the consequent distress they may feel. The services on offer at RDAC have been expanded this year to include a new skin diagnostic clinic and an expansion of urological diagnostic services. Plans are in place to expand the RDAC s remit to include head and neck cancers and sarcomas.
19 Diagnosis About The Royal Marsden 19 Diagnosis is crucial as patients need to be given the most appropriate treatment for their cancer type as quickly as possible. Our speed and expertise in molecular diagnostics means that tumours can be sub-classified quickly and the results used to plan a personalised course of treatment. Dr David Gonzalez de Castro, Head of the Molecular Diagnostics Laboratory
20 What we do 20 Annual Report and Accounts 2009/10 Treatment Our research into the biology of cancer is helping us to identify and map the unique characteristics of each patient s tumour. This directly influences the choices our team of experts make in planning an individualised course of therapy when treatment is necessary. We offer patients access to all modalities of therapies and services, from the latest robotic surgery to pioneering chemotherapy and radiotherapy. This year, we have continued to invest in expanding our comprehensive range of services, building new state-of-the-art facilities and offering leading-edge treatments. Comprehensive treatment Comprehensive breast services Patients being treated in our Breast Unit have access to a comprehensive range of services including our one-stop diagnostics clinic, breast surgery, plastic surgery (with a full range of breast reconstruction options), radiotherapy, chemotherapy (including cuttingedge research activity) and our lymphoedema service. Professor Ian Smith, the Head of the Breast Unit, was one of the pioneers of neo-adjuvant chemotherapy which involves chemotherapy being given before surgery. This treatment is now routinely offered when appropriate and works by shrinking tumours prior to surgery, allowing women who would have needed a mastectomy to have breastconserving surgery instead. techniques such as intensity modulated and partial organ radiotherapy (IMPORT High) with the aim of reducing the dose and subsequent harm to normal tissue. A new heart-sparing radiotherapy technique for women with leftsided breast cancer uses a special breathing controller that allows the treatment to be given only as the heart naturally moves away from the chest wall with respiration. Comprehensive prostate services The Urology Unit offers a uniquely comprehensive service with the latest techniques in robotic surgery, intensity-modulated and image-guided radiotherapy (IMRT and IGRT respectively), and access to clinical trials which are changing the standard of treatment worldwide. The comprehensive nature of the services we offer at The Royal Marsden is founded on the principle of a multidisciplinary team (MDT) approach. It means that a range of experts work together to plan each patient s treatment in order to identify the most appropriate course of therapy for that individual. Members of the MDT may include a surgeon, medical oncologist, radiotherapist, pathologist, radiologist and specialist nurse. This approach is common to all of our units, including our Breast and Urology Units. Our Breast Unit continues to develop new ways to improve the patient experience. Their work focuses on maintaining efficiency and minimising toxicity throughout treatment. A new type of surgery is available involving oncoplastic techniques - a less invasive surgery meaning the cosmetic outcome for women is much better. New molecular targets help to identify those patients who will really benefit from chemotherapy and those for whom it would not be the best type of treatment. Improvements to the targeting of radiotherapy are also being examined using innovative Our Urology Unit has pioneered the use of active surveillance which aims to individualise care by selecting only those men with significant prostate cancers for curative treatment. Those on active surveillance are closely monitored using prostate specific antigen (PSA) blood tests and repeat prostate biopsies, avoiding the negative side effect of treatment. The choice between continued observation and curative treatment is based on evidence of disease progression during this monitoring.
21 Treatment About The Royal Marsden 21 Multi-disciplinary team working ensures our patients have immediate access to a comprehensive range of treatments including surgery, radiotherapy and chemotherapy all under one roof. This ultimately sets them on the best personalised treatment course for their particular tumour type and helps to achieve the best outcome for them. Dr Christopher Nutting, Consultant Clinical Oncologist and Clinical Unit Head, Head and Neck Unit
22 What we do: Treatment 22 Annual Report and Accounts 2009/10 For patients requiring surgery, the da Vinci S robotic surgical system continues to improve outcomes. Patients operated on by the da Vinci S robot have been shown to suffer less from incontinence, normally spend as little as hours in hospital and experience less disease recurrence than those undergoing traditional open surgery prostatectomies. The da Vinci S has now been used in more than 800 operations and The Royal Marsden continues to perform the largest number of these surgeries within both the NHS and private sectors in the UK. The Unit has also invested in the latest technology that allows precise tracking of prostate tumours during external beam radiation therapy. We are the first cancer centre in the UK to offer the Calypso System which provides real-time tumour position information. We are also the first to have the ExacTrac system which is another image-guided system that allows more accurate targeting of treatment. The Unit works closely with the Drug Development Unit and the ICR so that prostate cancer patients have access to the latest randomised trials and drugs including abiraterone. Results from the latest Phase II abiraterone study are encouraging for men who have exhausted standard treatment options with about half the patients in the study showing a substantial reduction in levels of PSA in their blood. Leading-edge practice and facilities The Royal Marsden remains at the forefront of cancer treatment and, over the last year, we have invested in building state-of-theart facilities and acquiring the latest technology. Our clinical teams have also contributed to defining leading-edge practice by investigating the benefits of innovative treatment methods which offer patients better outcomes. Offering novel radiotherapy One of the largest international prostate radiotherapy trials, set to change the practice of radiotherapy, is being carried out by Professor David Dearnaley. He has led the development of an IMRT technique which shapes the radiation beam to the exact treatment area. This means that larger doses of radiotherapy can be delivered precisely to the cancer while reducing damage to the surrounding healthy tissue and resulting treatment-related side effects. We are the first hospital in the UK to implement Volumetric Modulated Arc Therapy (VMAT), a treatment machine that is able to deliver radiotherapy in continuous sweeping arcs. This technology allows us to deliver a treatment that is faster and more accurate, potentially involving fewer visits and decreasing a patient s recovery time. The Royal Marsden will be one of the first hospitals in the country to install the very latest in radiotherapy technology the CyberKnife. It will be based at our Chelsea site and will be available for NHS patients with tumours in the head and neck, liver, lung, pancreas, prostate and spinal cord from early CyberKnife delivers hundreds of beams of high dose radiation from a wide variety of angles using a robotic arm. Its pinhead accuracy means that CyberKnife can target tumours in places where surgery would be dangerous and deliver high doses of radiation targeted at the tumour, reducing the dose to normal tissue, often resulting in fewer treatments being needed. Improving the delivery of chemotherapy A new Ambulatory Care Centre is due to open in the centre of the hospital in Chelsea in autumn The new facility will house a new purpose-built Medical Day Unit (MDU) and a new Clinical Assessment Unit (CAU) where patients can be assessed and treated in a streamlined and efficient manner. The MDU includes 30 chairs situated in modern booths for privacy and dignity. Patients
23 About The Royal Marsden 23 As a world-renowned cancer centre, it is vital that we continue to invest in leading-edge radiotherapy technology, including CyberKnife for image guidance, and trial new techniques to ensure precision-targeted radiotherapy that can potentially offer higher doses in fewer sessions and with less side effects. This can only benefit our patients. Dr Vincent Khoo, Consultant Clinical Oncologist and Head of Radiotherapy will have access to chair-side entertainment systems including internet access. The number of consultation rooms has been increased and a satellite pharmacy will be located in the Unit to improve speed and efficiency of drug dispensing and advice. The new CAU will be an area dedicated to making sure that unwell patients can be seen quickly, assessed by specialist nurses and reviewed by the team so that treatment can commence with minimal delay. Increasing our surgical capacity In January 2010, four new operating theatres in the Wolfson Surgical Suite at our Chelsea site became Treatment fully operational following the successful completion of Phase 1 of our extensive rebuilding programme.
24 What we do: Treatment 24 Annual Report and Accounts 2009/10 Two of these modern theatres are purpose-built to provide better facilities for minimally invasive surgery. When this rebuild is fully completed, our theatre complex will also have a new 14 bay recovery area fitted with the latest monitoring equipment which is fully integrated with theatres and the Critical Care Unit (CCU). The new recovery area will be in a central location which will decrease the distance and time patients have to travel from theatres. The critical care service at The Royal Marsden provides life support for patients following major surgery as well as those with complications of either their disease or treatment. We have the only specialised cancer CCU in the UK and audits demonstrate that outcomes for patients are excellent. A new 19 bed CCU is due to open in summer 2010, allowing us to treat more patients who require this specialised support. The focus of the new Unit is on care tailored to the needs of each patient in an excellent environment with natural light and a majority of single-room accommodation. Glass that opacifies at the touch of a button provides privacy. There is access to an outside balcony from each room and an entertainment We are very much looking forward to the opening of the Ambulatory Care Centre. It will be a major step forward in ensuring that the team can deliver the very best of care to those who have put their faith in us. Dr Sanjay Popat, Consultant Medical Oncologist system for patients recovering from surgery or other treatment. For the first time, two rooms will be dedicated to the specialised care of adolescents. These larger rooms will have space for parents to stay and internet and social networking access. A co-located high dependency unit will also provide care either for patients stepping down from intensive care or with a lower acuity. A key feature of the new Unit is the modern monitoring and IT system. Nursing and medical staff will no longer have to scribe patient observations onto daily recording sheets. Instead, this data will be saved to an electronic charting system linked to theatres,
Inova Breast Care Institute At the Inova Breast Care Institute, our commitment is to provide expert care for you, every step of the way. Our multidisciplinary team of more than 80 experts provides a full
Breast Health Program Working together, for your health. Breast Health Program The Breast Health Program at The University of Arizona Cancer Center offers patients a personalized approach to breast cancer,
Prostate Cancer Treatments as unique as you are UCLA Prostate Cancer Program Prostate cancer is the second most common cancer among men. The UCLA Prostate Cancer Program brings together the elements essential
UCSF HEALTH Cancer Services for Adults and Children Our world-class clinical and research programs are engaged in the urgent effort to cure cancers and, where cures currently elude us, transform cancer
West Florida Physician Office Building Johnson Ave. University Pkwy. Olive Road N. Davis Hwy. For more information on West Florida Cancer Center: 850-494-5404 2130 East Johnson Avenue Pensacola, Florida
The Center for Cancer Care Comprehensive and compassionate care Welcome to the Center for Cancer Care The Center for Cancer Care at Exeter Hospital provides comprehensive, compassionate care for a wide
1 A guide to prostate cancer clinical trials In this fact sheet: What is a clinical trial? Why are trials done? What are trials looking into at the moment? How are clinical trials done? Should I take part
An estimated 220,000 women in the United States are diagnosed with breast cancer each year, and one in eight will be diagnosed during their lifetime. While breast cancer is a serious disease, most patients
Leading cancer treatments and improving outcomes for patients: Our Why? Our patients will always come first and no matter what our vision is for the years ahead, this ethos of will always remain the same.
An Introduction to PROSTATE CANCER Being diagnosed with prostate cancer can be a life-altering experience. It requires making some very difficult decisions about treatments that can affect not only the
ESSENTIALS Breast Cancer Take things one step at a time. Try not to be overwhelmed by the tidal wave of technical information coming your way. Finally you know your body best; you have to be your own advocate.
Follow-up care plan after treatment for breast cancer A guide for General Practitioners This leaflet provides information for GPs on the follow-up care required by women who had breast cancer. It is for
The treatment you receive will depend on your lung cancer type, for example, whether you have a non-small cell lung cancer Adenocarcinoma or Squamous cell carcinoma, and if this is a sub-type with a mutation.
Specific Standards of Accreditation for Residency Programs in Radiation Oncology 2015 VERSION 3.0 INTRODUCTION The purpose of this document is to provide program directors and surveyors with an interpretation
All men should know they are having a PSA test and be informed of the implications prior to testing. This booklet was created to help primary care providers offer men information about the risks and benefits
Produced November 2010 Next revision due November 2012 How do I find the best place to get treatment for my lymphoma? Introduction Fortunately this is not a question that patients with cancers of the blood
National Cancer Patient Experience Programme 2010 National Survey Published January 2011 The National Cancer Patient Experience Survey Programme is being undertaken by Quality Health on behalf of the Department
> > > > > > > > > > > > > > > > > > > > What does the AHSC mean for you? Our vision for the UK s first Academic Health Science Centre a mini-guide for patients Quicker access to new medicines and new treatments
Board of Directors Meeting 23 rd July 2014 (BDA/14/26) part Performance Report Monitor Key Indicators Status: A Paper for Information History: Amanda Pritchard Chief Operating Officer Page 1 of 10 Performance
Guide to Private Medical Insurance Contents About the Exeter 4 Why private medical insurance? 5 Product highlights 6 Cover and benefits 10 Getting the right premium 15 How to apply 16 Claims overview 21
Ushering in a new era of cancer medicine Center is ushering in a new era of cancer medicine. Progress that could not even be imagined a decade ago is now being realized in our laboratories and our clinics.
Edinburgh Breast Unit Treatment: Questions and Answers about Breast Cancer in South East Scotland* These questions and answers will provide an overview of the standard approaches for treating breast cancer
Guideline for the Follow Up of Patients Following Treatment for Breast Cancer Date Approved by Network Governance July 2012 Date for Review July 2015 Page 1 of 6 1 Scope of the Guideline This guideline
Cancer Treatment Benefit In Hong Kong, more than 27,000 men and women are newly-diagnosed with cancer each year 1, which means on average one new case is recorded every 20 minutes. Currently 1 in 4 men
London cancer services: Proposed model of care Summary 1 Contents Foreword from the project board 3 Foreword from the patient panel 4 London cancer services: a proposed model of care 8 The nature of the
For Immediate Release 4 February 2015 WHAT S CANCER GOT TO DO WITH FOOD? Food is a major element in cancer prevention and care. Not only can cancer risk be reduced with a healthy lifestyle; nutritional
Ask Us About Clinical Trials Clinical Trials and You. Our specialists and researchers are at the forefront of their fields and are leading the way in developing new therapies and procedures for diagnosing
Lung Cancer & Mesothelioma 2011-2015 Annex G Mesothelioma 1. The vision for mesothelioma services is set out in the Mesothelioma Framework issued by DH on 26 February 2007 (supported by the British Thoracic
PRACTICE FRAMEWORK AND COMPETENCY STANDARDS FOR THE PROSTATE CANCER SPECIALIST NURSE MARCH 2013 MONOGRAPHS IN PROSTATE CANCER OUR VISION, MISSION AND VALUES Prostate Cancer Foundation of Australia (PCFA)
Breakthrough Treatment Options for Breast Cancer Guest Expert: Lyndsay, MD Associate Professor of Medical Oncology, Yale Cancer Center www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center
Division of Cancer Surgery Information Guide Professor Sandy Heriot Director - Division Cancer Surgery Professor Michael Henderson Deputy Director Division Cancer Surgery Executive Sponsor Education and
Nursing, Risk & Quality (NRQ) Directorate Shelley Dolan Chief Fellowship Clinical Nursing Fellow Fellow Psycho-sexual Practice Strategic Lead For Health s Delivery (Division 1) CRN: South London Assistant
GP Round Up Issue 55 October 2014 Contents GP Round Up Introduction by Alistair Flowerdew Medical Director... 1 Observation ward opens in Emergency Department... 2 Orthopaedic Elective Centre to open in
Phasel clinical trials: what are they all about? Information for people wanting to know more about early clinical trials in cancer, Belfast City Hospital NORTHERN IRELAND CANCER TRIALS CENTRE Introduction
Research Strategy 2012 2020 Foreword Acknowledgements We are particularly indebted to Professor David Neal and Professor Michael Olson for their expert assessment of the trends, gaps and bottlenecks in
Consultation Response Medical profiling and online medicine: the ethics of 'personalised' healthcare in a consumer age Nuffield Council on Bioethics Response by the Genetic Interest Group Question 1: Health
dedicated to curing BREAST CANCER When you are diagnosed with breast cancer, you need a team of specialists who will share their knowledge of breast disease and the latest treatments available. At Cancer
Treatment options for recurrent ovarian cancer There are a number of treatment options for women with recurrent ovarian cancer. Chemotherapy is the treatment most commonly offered and on occasion, surgery
Patient Electronic Alert to Key-worker System (PEAKS) Guidelines This procedural document supersedes: PAT/EC 4 v.1 Guidelines for Patient Electronic Alert to Key-worker systems (PEAKS). Did you print this
0116 250 2811 firstname.lastname@example.org www.btog.org @BTOGORG British Thoracic Oncology Group (BTOG) Annual Report - April 2014 to March 2015 BTOG s Aim BTOG is the multi-disciplinary group for professionals
Ali A. Kader, S. (2010). Breast cancer awareness for women and men. UCQ Nursing Journal of Academic Writing, Winter 2010, 70 76. BREAST CANCER AWARENESS FOR WOMEN AND MEN by Samar Ali A. Kader Two years
cruk.org WHAT WE DO Our vision is to bring forward the day when all cancers are cured. Thousands of people are alive today thanks to research. Animal studies have played an important part in this progress.
april 2007 information about Inflammatory breast cancer What is inflammatory breast cancer? Inflammatory breast cancer is a rare and rapidly growing form of breast cancer. Unlike other breast cancers which
Staff will recall at the end of April, we sent out a special newsletter which highlighted some of our achievements over the last 10 years. To coincide with the NHS s birthday on 5th July this is the second
Lung Cancer Consultant Outcomes Publication Introduction This report describes the outcomes of individual consultant thoracic and cardiothoracic surgeons who carry out surgery for lung cancer. It has been
Questions to ask your doctor about Prostate Cancer and selecting a treatment facility The Basics Establishing an open dialogue with a doctor provides you with the opportunity to learn specific information
SAFE AND INNOVATIVE RADIATION THERAPY Advanced treatment options including the CyberKnife System Surgery-Free Cancer Treatment in Suffolk County If you need treatment for cancer or non-cancerous tumors,
Strategic Plan 2011-2016 approved by the Board of Trustees on 14 July 2011 revised May 2012 Contents Our Vision, our Mission 3 Our values 4 Introduction from the Chief Executive 5 Strategic direction 6
PATIENT INFORMATION SHEET Surgical and large bore pleural procedures in Malignant pleural Mesothelioma And Radiotherapy Trial (SMART trial) Stoke Mandeville Hospital Mandeville Road Aylesbury Buckinghamshire
Xxxxxxxxxxxxxxxxxxxxx A guide for adult patients receiving Proton Beam Therapy abroad Adult PBT Guide 2013 1 Contents Proton Beam Therapy explained (P4) What is Radiotherapy? What is Proton Beam Therapy?
Brain & CNS cancers 2015 Annex B Epidemiology 1. The incidence of brain & CNS tumours in England was reported to be just under 4,000 in 2007. 1 This is expected to increase further with an aging population
For Immediate Release Oct. 8, 2012 When it comes to treating breast cancer, doing less does more October is Breast Cancer Awareness Month SEATTLE Oncologists and researchers are discovering that when it
National Clinical Programmes Section 3 Background information on the National Clinical Programmes Mission, Vision and Objectives July 2011 V0. 6_ 4 th July, 2011 1 National Clinical Programmes: Mission
Excellence & Choice A Consultation on Older People s Services January 2009 CONTENTS 1. Introduction...3 2. Guiding principles for the delivery of services for older people...5 3. How are services for older
PSA Testing for Prostate Cancer An information sheet for men considering a PSA Test What is the aim of this leaflet? Prostate cancer is a serious condition. The PSA test, which can give an early indication
Waiting Times for Suspected and Diagnosed Cancer Patients Waiting Times for Suspected and Diagnosed Cancer Patients 1 Waiting Times for Suspected and Diagnosed Cancer Patients Prepared by Jonathan Pearson,
Cancer treatment TOP EUROPEAN CANCER EXPERTISE The path to recovery 0% LAND OF HIGH QUALITY HEALTHCARE Located in Finland, a land of high quality healthcare, Helsinki University Hospital is regarded as
Understanding your pathology report 2 Contents Contents Introduction 3 What is a pathology report? 3 Waiting for your results 4 What s in a pathology report? 4 Information about your breast cancer 5 What
OVARIAN CANCER TREATMENT Cancer Care Pathways Directorate Tailored Information in Cancer Care (TICC) Sir Anthony Mamo Oncology Centre National Cancer Plan May 2015 Contents About this booklet 1 The Ovaries
Paper: PB.28.01.16/05 Title: Cancer Taskforce strategy implementation Lead Director: Bruce Keogh, National Medical Director Cally Palmer, National Cancer Director BOARD PAPER - NHS ENGLAND Purpose of Paper:
THORACIC ONCOLOGY MULTIDISCIPLINARY TEAM MEETINGS: OPERATIONAL POLICY EXECUTIVE SUMMARY 1. All patients in Lothian with thoracic malignancies should be discussed at designated times in pathway (see App
Breast Cancer Presentation by Dr Mafunga Breast cancer in the UK Breast cancer is the second most common cancer in women. Around 1 in 9 women will develop breast cancer It most commonly affects women over
Information for patients and the public and patient information about DNA / Biobanking across Europe BIOBANKING / DNA BANKING SUMMARY: A biobank is a store of human biological material, used for the purposes
TARGET YOUR FUTURE RADIATION ONCOLOGY A Career in Radiation Oncology YOUR CHOICE SAVE LIVES Take the first step towards a career in Radiation Oncology Visit www.acareerinradiationoncology.com.au What is
A Health and Wellbeing Strategy for Bexley Listening to you, working for you www.bexley.gov.uk Introduction FOREWORD Health and wellbeing is everybody s business, and our joint aim is to improve the health
Bath & North East Somerset Council MEETING/ DECISION MAKER: MEETING/ DECISION DATE: Health & Wellbeing Select Committee 29 th July 2015 EXECUTIVE FORWARD PLAN REFERENCE: TITLE: Royal United Hospitals Bath
Cancer research in the Midland Region the prostate and bowel cancer projects Ross Lawrenson Waikato Clinical School University of Auckland MoH/HRC Cancer Research agenda Lung cancer Palliative care Prostate
Media Release April 7, 2009 For Immediate Release NEW HYBRID IMAGING TECHNOLOGY MAY HAVE BIG POTENTIAL FOR IMPROVING DIAGNOSIS OF PROSTATE CANCER London, Ontario Improved hybrid imaging techniques developed
BMI Werndale Hospital Quality Accounts April 2013 to March 2014 Chief Executive s Statement Welcome to our Quality Accounts 2014, the fifth year we have published this data. The information presented here
Treating Mesothelioma - A Quick Guide Contents This is a brief summary of the information on Treating mesothelioma from CancerHelp UK. You will find more detailed information on the website. In this information
BREAST CANCER PATHOLOGY FACT SHEET Version 4, Aug 2013 This fact sheet was produced by Breast Cancer Network Australia with input from The Royal College of Pathologists of Australasia I m a nurse and know
Treatment overview for lung cancer This information is an extract from the booklet Understanding lung cancer. You may find the full booklet helpful. We can send you a free copy see page 5. Contents How
BREAST CANCER IN THE 21 st CENTURY The Carolinas Medical Center NorthEast Experience Garry Schwartz, MD The American Cancer Society's most recent estimates for breast cancer in the United States for 2009
Improving healthcare for people with long-term conditions UWe-book: Number Two 1 Health and Well-being At UWE our research and development is real and dynamic, identifying problems and providing solutions
Improving Emergency Care in England REPORT BY THE COMPTROLLER AND AUDITOR GENERAL HC 1075 Session 2003-2004: 13 October 2004 LONDON: The Stationery Office 11.25 Ordered by the House of Commons to be printed
National Framework for Excellence in Lung Cancer Screening and Continuum of Care declaration of purpose Rights and Expectations THE RIGHTS OF THE PEOPLE Lung cancer kills more Americans than the next four
National Cancer Rehabilitation Pathways Rachel Atkinson AHP Lead May 2011 National Cancer and Palliative Care Rehabilitation workforce Project One of the objectives was to produce 9 tumour specific, evidence
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Adjuvant Therapy for Breast
Association internationale sans but lucratif AVENUE DE LA COURONNE, 20 BE- 1050 BRUSSELS www.uems.net International non-profit organisation T +32 2 649 51 64 F +32 2 640 37 30 email@example.com Training Requirements
Non-Small Cell Lung Cancer Therapies Guest Expert: Roy, MD, PhD Assistant Professor of Therapeutic Radiology Scott, MD Assistant Professor of Medical Oncology www.wnpr.org www.yalecancercenter.org Welcome